A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB plus ANASTROZOLE COMPARED TO LAPATINIB plus LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR plus ) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

被引：0
|
作者：
McNamara, S. [1 ]
Moore, L. [1 ]
Ray, J. [2 ]
机构：
[1] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[2] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A269 / A269
页数：1
相关论文
共 50 条
  • [1] Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET plus LAP) versus anastrozole plus trastuzumab (ANA plus TZ) as first-line treatment for postmenopausal women with HER2+and HR+ metastatic breast cancer (MBC) from the UK National Health Service (NHS) perspective
    Hastings, V.
    Delea, T. E.
    Amonkar, M.
    Lykopoulos, K.
    Diaz, J.
    Johnston, S. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A Q-TWiST analysis of lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive (HR plus ) metastatic breast cancer (MBC)
    Sherrill, B.
    Amonkar, M.
    Sherif, B.
    Maltzman, J.
    O'Rourke, L.
    Johnston, S.
    EJC SUPPLEMENTS, 2009, 7 (02): : 275 - 275
  • [3] Cost-utility analysis of Palbociclib plus letrozole and ribociclib plus letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model
    Darvishi, Ali
    Daroudi, Rajabali
    Fazaeli, Ali Akbar
    HEALTH ECONOMICS REVIEW, 2023, 13 (01)
  • [4] COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED/METASTATIC BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE
    Hettle, R.
    Suri, G.
    Misty, R.
    Chandiwana, D.
    Lee, A.
    VALUE IN HEALTH, 2017, 20 (09) : A433 - A433
  • [5] Lapatinib plus letrozole compared with letrozole alone as first-line therapy in hormone receptor positive HER2+metastatic breast cancer (MBC): A quality-of-life (QOL) analysis
    Sherif, B. N.
    Sherrill, B.
    Amonkar, M.
    Wu, Y.
    Maltzman, J.
    O'Rourke, L.
    Johnston, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Cost-effectiveness of lapatinib plus letrozole in HER2-positive, hormone receptor-positive metastatic breast cancer in Canada
    Delea, T. E.
    Amdahl, J.
    Chit, A.
    Amonkar, M. M.
    CURRENT ONCOLOGY, 2013, 20 (05) : E371 - E387
  • [7] Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective
    Mistry, Rohit
    May, Jessica R.
    Suri, Gaurav
    Young, Kate
    Brixner, Diana
    Oderda, Gary
    Biskupiak, Joseph
    Tang, Derek
    Bhattacharyya, Subrata
    Mishra, Dinesh
    Bhattacharyya, Devarshi
    Dalal, Anand A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (06): : 514 - +
  • [8] eLEcTRA trial: Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first line treatment in patients with hormone-receptor-positive, HER2-positive metastatic breast cancer (MBC)
    Baumgaertner, A. K.
    Fasching, P.
    Paepke, S.
    Kubista, E.
    Barsoum, M.
    Wallwiener, D.
    Ragosch, V.
    Aulitzky, W.
    Prechtl, A.
    Reimer, T.
    Thomssen, C.
    Jaenicke, F.
    Harbeck, N.
    Huober, J.
    ONKOLOGIE, 2010, 33 : 7 - 8
  • [9] Comparison of the cost-effectiveness of upfront letrozole or anastrozole versus tamoxifen for early breast cancer in hormone receptor positive (HR plus ) postmenopausal women the Cypriot perspective
    Andreopoulos, D.
    Karnon, J.
    Kaura, S.
    EJC SUPPLEMENTS, 2008, 6 (07): : 126 - 127
  • [10] SYSTEMATIC REVIEW OF LAPATINIB PLUS LETROZOLE WITH OTHER FIRST LINE TREATMENTS FOR HORMONE POSITIVE (HR+) HER2+ADVANCED OR METASTATIC BREAST CANCER (MBC)
    Riemsma, R.
    Forbes, C. A.
    Amonkar, M.
    Lykopoulos, K.
    Diaz, J. R.
    Kleijnen, J.
    Rea, D. W.
    VALUE IN HEALTH, 2010, 13 (07) : A253 - A253
12345